Opus Genetics Stock Performance
| IRD Stock | 2.31 0.19 7.60% |
On a scale of 0 to 100, Opus Genetics holds a performance score of 4. The company holds a Beta of 0.96, which implies possible diversification benefits within a given portfolio. Opus Genetics returns are very sensitive to returns on the market. As the market goes up or down, Opus Genetics is expected to follow. Please check Opus Genetics' expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Opus Genetics' historical price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Opus Genetics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Opus Genetics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.60) | Five Day Return (7.23) | Year To Date Return 8.96 | Ten Year Return 79.07 | All Time Return 79.07 |
Last Split Factor 1:4 | Dividend Date 2020-11-06 | Last Split Date 2020-11-06 |
1 | Opus Genetics Announces 23 Million Registered Direct Offering | 11/06/2025 |
2 | Subdued Growth No Barrier To Opus Genetics, Inc. With Shares Advancing 27 | 12/11/2025 |
3 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 12/16/2025 |
4 | Acquisition by Gallagher Cam of 83000 shares of Opus Genetics at 1.9689 subject to Rule 16b-3 | 12/29/2025 |
5 | Acquisition by Gallagher Cam of 33000 shares of Opus Genetics subject to Rule 16b-3 | 12/31/2025 |
6 | Acquisition by Gallagher Cam of 67000 shares of Opus Genetics subject to Rule 16b-3 | 01/06/2026 |
7 | Disposition of 50 shares by Zaremba Rabourn Amy of Opus Genetics at 1.93 subject to Rule 16b-3 | 01/09/2026 |
8 | Disposition of 3390 shares by Zaremba Rabourn Amy of Opus Genetics at 2.1 subject to Rule 16b-3 | 01/16/2026 |
9 | BTIG Initiates Coverage on Opus Genetics with a Buy Rating - GuruFocus | 01/20/2026 |
10 | Acquisition by Robert Gagnon of 400000 shares of Opus Genetics subject to Rule 16b-3 | 01/22/2026 |
11 | Opus Genetics, Inc. Receives Consensus Rating of Moderate Buy from Analysts - MarketBeat | 01/23/2026 |
12 | Acquisition by Magrath George of 4836 shares of Opus Genetics subject to Rule 16b-3 | 01/26/2026 |
13 | Where Opus Genetics Stands With Analysts - Benzinga | 01/28/2026 |
| Begin Period Cash Flow | 50.5 M | |
| Total Cashflows From Investing Activities | 1.2 M |
Opus Genetics Relative Risk vs. Return Landscape
If you would invest 214.00 in Opus Genetics on November 2, 2025 and sell it today you would earn a total of 17.00 from holding Opus Genetics or generate 7.94% return on investment over 90 days. Opus Genetics is generating 0.214% of daily returns assuming volatility of 4.2426% on return distribution over 90 days investment horizon. In other words, 38% of stocks are less volatile than Opus, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opus Genetics Target Price Odds to finish over Current Price
The tendency of Opus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.31 | 90 days | 2.31 | about 18.17 |
Based on a normal probability distribution, the odds of Opus Genetics to move above the current price in 90 days from now is about 18.17 (This Opus Genetics probability density function shows the probability of Opus Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon Opus Genetics has a beta of 0.96. This usually indicates Opus Genetics market returns are highly-sensitive to returns on the market. As the market goes up or down, Opus Genetics is expected to follow. Additionally Opus Genetics has an alpha of 0.4929, implying that it can generate a 0.49 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Opus Genetics Price Density |
| Price |
Predictive Modules for Opus Genetics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Opus Genetics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Opus Genetics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Opus Genetics is not an exception. The market had few large corrections towards the Opus Genetics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Opus Genetics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Opus Genetics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.49 | |
β | Beta against Dow Jones | 0.96 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | 0.11 |
Opus Genetics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Opus Genetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Opus Genetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Opus Genetics had very high historical volatility over the last 90 days | |
| Opus Genetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 10.99 M. Reported Net Loss for the year was (57.53 M) with loss before taxes, overhead, and interest of (12.79 M). | |
| Opus Genetics generates negative cash flow from operations | |
| Opus Genetics has a poor financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Where Opus Genetics Stands With Analysts - Benzinga |
Opus Genetics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Opus Stock often depends not only on the future outlook of the current and potential Opus Genetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Opus Genetics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 26.7 M | |
| Cash And Short Term Investments | 30.3 M |
Opus Genetics Fundamentals Growth
Opus Stock prices reflect investors' perceptions of the future prospects and financial health of Opus Genetics, and Opus Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opus Stock performance.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 142.66 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Price To Book | 28.89 X | ||||
| Price To Sales | 11.78 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Earnings Per Share | (1.86) X | ||||
| Market Capitalization | 172.41 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
About Opus Genetics Performance
By analyzing Opus Genetics' fundamental ratios, stakeholders can gain valuable insights into Opus Genetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Opus Genetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Opus Genetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (2.79) | (2.65) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | (9.84) | (9.35) |
Things to note about Opus Genetics performance evaluation
Checking the ongoing alerts about Opus Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opus Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opus Genetics had very high historical volatility over the last 90 days | |
| Opus Genetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 10.99 M. Reported Net Loss for the year was (57.53 M) with loss before taxes, overhead, and interest of (12.79 M). | |
| Opus Genetics generates negative cash flow from operations | |
| Opus Genetics has a poor financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Where Opus Genetics Stands With Analysts - Benzinga |
- Analyzing Opus Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opus Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Opus Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opus Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opus Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opus Genetics' stock. These opinions can provide insight into Opus Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |